Infliximab Market New Innovations and Future Expansion 2023-2031
Pune, India - (NewMediaWire) - March 3, 2023 - "Infliximab" Size, Scope, and Forecast 2023-2031 report has been added to the Market Research Archive of Absolute Reports. Industry experts and researchers have offered an authoritative and concise analysis of the Global Infliximab with respect to various aspects such as growth factors, challenges, restraints, developments, trends, and opportunities for growth. This report will surely be a handy tool for market players to come up with effective strategies with the aim of strengthening their positions in the market.
What is the Infliximab growth?
Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. The Chinese infliximab market is completely dominated by Janssen, a Johnson & Johnson company, until 2021. Two local Chinese companies, Taizhou Mabtech Pharmaceutical Co., Ltd. and Hisun Biopharmaceutical Co., Ltd. are launching infliximab in 2021, making Janssen's infliximab a challenge in the Chinese market.
According to market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.9% in 2020 and reached CNY335.89 million in 2021. The CAGR of infliximab’s sales value in China is approximately 19.0% from 2017 to 2021.
According to market research and expert interviews, Researchers sees different trends in 2022 and from 2023 to 2026 in China’s infliximab market.
Get a Sample PDF of report - https://www.absolutereports.com/enquiry/request-sample/21377469
Sales volume and value of infliximab in China are expected to decline in 2022 as the Chinese government implements a strict "COVID-19 dynamic zeroing" policy that will prevent many healthcare facilities in China from operating normally. It is expected that the Chinese government will relax the COVID-19 control policy from early 2023 onwards, and thus the sales volume and sales value of infliximab in China will show a recovery growth from 2023-2026.
Browse Detailed TOC, Tables and Figures with Charts which is spread across 40 Pages that provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche sector.
1. Does this report consider the impact of COVID-19 and the Russia-Ukraine war on the Infliximab?
Yes. As the COVID-19 and the Russia-Ukraine war are profoundly affecting the global supply chain relationship and raw material price system, we have definitely taken them into consideration throughout the research, in Chapters, we elaborate at full length on the impact of the pandemic and the war on the Infliximab Industry.
Final Report will add the analysis of the impact of Russia-Ukraine War and COVID-19 on this Infliximab Industry.
This report provides a pin-point analysis of changing dynamics and emerging trends in the Global Infliximab. Additionally, it provides a futuristic perspective on various factors that are likely to fuel the growth of the Global Infliximab in the coming years. Further, the authors of the report have shed light on the factors that may hinder the growth of the Global Infliximab.
Infliximab - Competitive and Segmentation Analysis:
2. How do you determine the list of the key players included in the report?
With the aim of clearly revealing the competitive situation of the industry, we concretely analyze not only the leading enterprises that have a voice on a global scale, but also the regional small and medium-sized companies that play key roles and have plenty of potential growth.
Top Key Players of the Global Infliximab
Janssen Biologics BV (REMICADE)
Short Description About Infliximab:
The Global Infliximab is anticipated to rise at a considerable rate during the forecast period, between 2023 and 2031. In 2023, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
This report studies the Infliximab, covering market size for segment by type, by application, by sales channel (Direct Channel, Distribution Channel), and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
This report provides detailed historical analysis of global market for Infliximab from 2015-2020, and provides extensive market forecasts from 2023-2031 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Infliximab.
Moreover, the impact of COVID-19 is also concerned. Since outbreak in December 2019, the COVID-19 virus has spread to all around the world and caused huge losses of lives and economy, and the global manufacturing, tourism and financial markets have been hit hard, while the online market/industry increase. Fortunately, with the development of vaccine and other effort by global governments and organizations, the negative impact of COVID-19 is expected to subside and the global economy is expected to recover.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and sub-segments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments.
3. What are your main data sources?
Both Primary and Secondary data sources are being used while compiling the report.
Primary sources include extensive interviews of key opinion leaders and industry experts (such as experienced front-line staff, directors, CEOs, and marketing executives), downstream distributors, as well as end-users.Secondary sources include the research of the annual and financial reports of the top companies, public files, new journals, etc. We also cooperate with some third-party databases.
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2023-2031) of the following regions are covered in Chapter 4 and Chapter 7:
- North America (United States, Canada and Mexico)
- Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil, Argentina, Columbia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa
Please find a more complete list of data sources in Chapters
1.To study and analyze the global Infliximab consumption (value) by key regions/countries, product type and application
2.To understand the structure of Infliximab by identifying its various sub segments.
3.Focuses on the key global Infliximab manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
4.To analyze the Infliximab with respect to individual growth trends, future prospects, and their contribution to the total market.
5.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
6.To project the consumption of Infliximab submarkets, with respect to key regions (along with their respective key countries).
7.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
8.To strategically profile the key players and comprehensively analyze their growth strategies.
Customization of the Report
4. Can I modify the scope of the report and customize it to suit my requirements?
Yes. Customized requirements of multi-dimensional, deep-level and high-quality can help our customers precisely grasp market opportunities, effortlessly confront market challenges, properly formulate market strategies and act promptly, thus to win them sufficient time and space for market competition.
Inquire more and share questions if any before the purchase on this report at - https://www.absolutereports.com/enquiry/pre-order-enquiry/21377469
Detailed TOC of Infliximab Market Insights and Forecast to 2031
1 Relevant Concepts of Infliximab
1.1 Indications for Infliximab
1.2 Development of Infliximab in China
1.3 Governmental Approval of Infliximab in China
1.4 The Impact of COVID-19 on Infliximab sales in China
2 Sales of Infliximab in China, 2017-2021
2.1 Sales Value of Infliximab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Infliximab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Infliximab by Dosage Form in China, 2017-2021
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Infliximab Manufacturers in China, 2017-2021
3.1 Analysis of Market Share of Major Infliximab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Janssen Biologics BV
3.2.1 Enterprise Profile
3.2.2 Sales of REMICADE (Janssen’s Infliximab) in China
4 Prices of Infliximab for Different Manufacturers in China, 2021-2022
4.1 Janssen Biologics BV (REMICADE)
5 Prospect of Chinese Infliximab drug Market, 2022-2031
5.1 Influential Factors of Chinese Infliximab Market Development
5.1.1 The Impact of COVID-19 on Chinese Infliximab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Infliximab Drugs Approved by Chinese Government, by 2022
Chart Sales Value of Infliximab in China, 2017-2021
Chart Sales Value of Infliximab in Regions of China, 2017-2021
Chart Sales Volume of Infliximab in China, 2017-2021
Chart Sales Volume of Infliximab in Regions of China,2017-2021
Chart Sales value and volume of infliximab injection in China 2017-2021
Chart Market Share of TOP3 Infliximab Manufacturers by Sales Value in China, 2017-2021
Chart Market Share of TOP3 Infliximab Manufacturers by Sales Volume in China, 2017-2021
Chart Profile of Janssen Biologics BV
Chart Sales Value of Janssen Biologics BV 's Infliximab in China, 2017-2021
Chart Sales Volume of Janssen Biologics BV 's Infliximab in China, 2017-2021
Chart Profile of Taizhou Mabtech Pharmaceutical Co., Ltd.
Chart Sales Value of Taizhou Mabtech Pharmaceutical Co., Ltd.’s Infliximab in China, 2017-2021
Chart Sales Volume of Taizhou Mabtech Pharmaceutical Co., Ltd. 's Infliximab in China, 2017-2021
Chart Hisun Biopharmaceutical Co., Ltd.
Chart Sales Value of Xi'an Hanfeng Pharmaceutical Co., Ltd.’s Infliximab in China, 2017-2021
Chart Sales Volume of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
Chart Prices of Janssen Biologics BV’s Infliximab (Remicade ®) in Parts of China, 2021-2022
Chart Prices of Taizhou Mabtech Pharmaceutical Co., Ltd.’s Infliximab (Leiting®) in Parts of China, 2021-2022
Chart Prices of Hisun Biopharmaceutical Co., Ltd.’s infliximab(Anbaite®) in Parts of China, 2021-2022
Chart Forecast on sales of infliximab in China 2022-2031
Purchase this report (Price 3200 USD for a single-user license) - https://www.absolutereports.com/purchase/21377469
Absolute Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At Absolute Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.
Organization: Absolute Reportsemail: email@example.com
Phone: US +1 424 253 0807 / UK +44 203 239 8187